Biosimilar Resources

Biosimilars are biologic medicines that are highly similar to already approved reference products, offering comparable safety, efficacy, and quality at a reduced cost. Our resources provide information on the use, benefits, and regulatory guidelines of biosimilars to help healthcare professionals improve patient access and manage treatment costs effectively. To learn more about biosimilars and biologics visit AMCP's Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) at bbcic.org.

Featured Resources

See All in Biosimilars
AMCP Podcast Series Featured Episode
Podcast

The Buzz Around Biosimilars: AMCP’s Actions for 2023

2023 will be a pivotal year for biosimilar success or failure. Health care expert Fred Goldstein sits down with Stanton Mehr of Biosimilars Review & Report, to discuss what lies in store for biosimilars and AMCP’s biosimilar initiatives this year.
AMCP Podcast Series Featured Episode
Podcast

Humira Biosimilars are Here! What Now?

Health care expert Fred Goldstein sits down with Melissa Andel, principal and founder of CommonHealth Solutions, to discuss the long-awaited launch of Humira biosimilars and what Amgen’s pricing strategy means for patients and payers.
Webinars

Bracing for the Impact of Biosimilars: Navigating Terrain in the U.S. Market Landscape

  • Tuesday, Jun. 11, 2024 at 2-3pm ET
AMCP 2023 Value of Managed Care Pharmacy Report
Resource

The Value of Managed Care Pharmacy

Managed care pharmacy and prescription drug coverage is a growing part of the American health care sector. AMCP launched the annual Access, Affordability, and Outcomes report to raise awareness of the existence, prevalence, and importance of managed care pharmacy.
Biosimilars, Prescription Digital Therapeutics, Formulary & Utilization Management, Health Disparities, Health Technology, Legislation & Regulation, Managed Care Practice Issues
A group of people in various workforces
Resource

Biosimilars for Employer Consultants

"Biosimilars for Employer Consultants" was created to provide background information on biosimilars and to provide considerations for consultants to discuss with their employer clients.
Biosimilars
AMCP Podcast Series Featured Episode
Podcast

Humira Biosimilars are Here! What Now?

Health care expert Fred Goldstein sits down with Melissa Andel, principal and founder of CommonHealth Solutions, to discuss the long-awaited launch of Humira biosimilars and what Amgen’s pricing strategy means for patients and payers.
AMCP Podcast Series Featured Episode
Podcast

The Buzz Around Biosimilars: AMCP’s Actions for 2023

2023 will be a pivotal year for biosimilar success or failure. Health care expert Fred Goldstein sits down with Stanton Mehr of Biosimilars Review & Report, to discuss what lies in store for biosimilars and AMCP’s biosimilar initiatives this year.
Meeting Proceedings & Findings

AMCP Biosimilars Operational Readiness Initiative

The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group launched in Q4 2022.
Biosimilars